Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.77%-0.49 ppLife Sciences Tools & Services1.42%-0.35 ppHealth Care Equipment2.61%-0.35 ppManaged Health Care1.83%-0.20 ppBiotechnology2.26%-0.15 ppHealth Care Services0.54%-0.13 ppHealth Care Supplies0.15%-0.05 ppHealth Care Technology0.03%+0.03 ppHealth Care Distributors0.38%-0.01 ppHealth Care Facilities0.25%+0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.26%
Industry change · 12M
-0.15 pp
Biotechnology · contribution
-0.146 pp
Company participation
88%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Aug 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Gilead Sciences → GILD | United States | $98.4bn | 0.238% | +0.085 pp | -0.066 pp | +7.6% | Yes |
| Moderna → MRNA | United States | $29.8bn | 0.072% | -0.033 pp | -0.065 pp | -31.5% | No |
| Biogen → BIIB | United States | $29.8bn | 0.072% | +0.009 pp | -0.051 pp | -23.4% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $128.0bn | 0.309% | +0.085 pp | +0.023 pp | +42.4% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $111.3bn | 0.269% | +0.093 pp | +0.021 pp | +43.3% | Yes |
| Incyte → INCY | United States | $12.6bn | 0.031% | +0.006 pp | -0.016 pp | +1.8% | Yes |
| AbbVie → ABBV | United States | $346.8bn | 0.838% | +0.294 pp | +0.011 pp | +38.7% | Yes |
| Amgen → AMGN | United States | $179.4bn | 0.433% | +0.120 pp | -0.004 pp | +34.1% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.